AMAG Pharmaceuticals — Q2 2016 Earnings Presentation
33 slides from AMAG Pharmaceuticals's earnings presentation, Aug 9, 2016
Slide 1: Forward-Looking Statements
Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, Ma
Slide 2: Q2-2016 Earnings Call Agenda
Q2-2016 Earnings Call Agenda 3 Q2-2016 and Recent Highlights 1 5 2016 Key Priorities and Closing Remarks 5 Q&A 6 2 Commercial Update 4 Financial Update 3 Pipeline Update
Slide 3: Strong Product & Services Revenue Growth
Strong Product & Services Revenue Growth GAAP Product & Services Revenue ($M) 1 AMAG acquired CBR in August 2015. 4 Makena CBR1 Feraheme +50% 2Q-2015 1Q-2016 2Q-2016 $84.7 $127.4 $109.1
Slide 4: Q2-2016 Highlights and Recent Events
Q2-2016 Highlights and Recent Events 5 Achieved record sales for both Makena and Feraheme Advanced Makena and Feraheme next generation development programs Completed Makena pilot PK studies and are preparing for definitive PK study Accelerated plans to conduct Makena comparative pain study Currently
Slide 5: Q2-2016 Highlights and Recent Events
Q2-2016 Highlights and Recent Events = Achieved record sales for both Makena and Feraheme = Advanced Makena and Feraheme next generation development programs - Completed Makena pilot PK studies and are preparing for definitive PK study - Accelerated plans to conduct Makena comparative pain study — C
Slide 6: Maternal Health: Makena Proven Commercial Execution Capabilities
MATERNAL HEALTH: MAKENA Proven Commercial Execution Capabilities Record Makena Sales ($M) +23% 7 Launched single-dose, preservative free formulation of Makena $63.6 $65.0 $78.4 $85.0 $95.0 Q2-2015 actual 1Q-2016 actual 2Q-2016 actual 3Q-2016 est. 4Q-2016 est.
Slide 7: Makena: Well Positioned in Large Market, Growing Share
8 Compounded Hydroxyprogesterone Caproate Makena2 Off Guidance3 Q2-2016 Demand Market Share2 $1B Market Opportunity1 MATERNAL HEALTH: MAKENA Well Positioned in Large Market, Growing Share Increase Makena @Home administration Signed new home health agreement with leading home health provider Increase
Slide 8: Cord Blood Registry: Attractive Recurring Revenue Stream
MATERNAL HEALTH: CORD BLOOD REGISTRY Attractive Recurring Revenue Stream Non-GAAP, Pro Forma CBR Revenue1 ($M) 1See slides 27-29 for reconciliations of GAAP to non-GAAP financial information. 2 Represents pro forma revenue. AMAG acquired CBR in August 2015. GAAP CBR Revenue ($M) 2 9 +5% +25% AMAG Pu
Slide 9: Cord Blood Registry: Primary Focus is Category Growth
10 MATERNAL HEALTH: CORD BLOOD REGISTRY Primary Focus is Category Growth 4M Annual U.S. Births Continue improvement in commercial execution and leverage field footprint Focused on emphasizing competitive advantages and market position Differentiate CBR’s offerings Enhanced messaging to capitalize on
Slide 10: Feraheme: Strong Commercial Execution & Differentiated Product
HEMATOLOGY/ONCOLOGY BUSINESS: FERAHEME Strong Commercial Execution & Differentiated Product Record Feraheme Sales 11 +18% Growth in key segments Both hospital and hematology/oncology segments continue to grow 1 Optimize net revenue per gram Continued sustainable & predictable broad patient access st
Slide 11: Pipeline Update
Pipeline Update AMAG Pharmaceuticals
Slide 12: Makena Subcutaneous Auto-Injector Development Program
Makena Subcutaneous Auto-Injector Development Program Designed for: Easier administration for healthcare providers Pre-filled, single-use – “One & done” Less painful injections Utilizes shorter and more narrow 27 gauge needle Working with proven device partner, Antares Two approved auto-injectors 13
Slide 13: Advancing the Makena Auto-Injector Program
14 Advancing the Makena Auto-Injector Program Completed pilot PK studies; preparing for definitive PK study Met with FDA to review planned sNDA filing Meeting clarified need to submit pain data with sNDA Pain study to be conducted concurrently with the definitive PK study Provides opportunity for 7
Slide 14: Preparing to Initiate Makena Studies for sNDA Submission
Preparing to Initiate Makena Studies for sNDA Submission Bioequivalence (BE) Study Comparative Pain Study Design Randomized open label parallel BE study Randomized open label parallel study Objective Demonstrate comparable bioavailability between SC and IM injections Compare average injection pain o
Slide 15: Feraheme Label Expansion Trial Underway
Feraheme Phase 3 Label Expansion Trial Underway Sample Size (N); Dosing Regimen N = ~2,000 subjects randomized in a 1:1 ratio to receive either Feraheme (500 mg) or Injectafer (750 mg). Dosed 2x seven days apart Key Entry Criteria Subjects with IDA and in whom intravenous iron treatment is indicated
Slide 16: Financial Update
Financial Update AMAG Pharmaceuticals
Slide 17: GAAP Total Revenue and Operating Income
GAAP Total Revenue and Operating Income GAAP Total Revenue ($M) 18 Makena CBR Feraheme Collaboration revenue1 GAAP Operating Income ($M) 1 Collaboration revenue of $39.2 million related to the termination of AMAG’s ex-US ferumoxytol marketing partnership agreement, of which $33.6 was non-cash and $5
Slide 18: Q2-2016 Financial Summary
Q2-2016 Financial Summary Note: See corresponding footnotes 4,6,7,8,9,10,12,13,14 on slide 28, and slides 27-29 for reconciliations of GAAP to non-GAAP financial information. * See slide 31 for share reconciliation. ($M, except per share data) Q2-2016 (GAAP) Adjustments Q2-2016 (Non-GAAP) Total reve
Slide 19: Strong Cash Flow Generation
Strong Cash Flow Generation 21 ($M) 6/30/16 12/31/15 Cash, cash equivalents and investments $546 $466 Convertible senior notes (2.5%) $200 $200 Term loan facility (4.75%) 337 346 2023 senior notes (7.875%) 500 500 Total debt (principal amount outstanding) $1,037 $1,046 ($M) 6/30/16 12/31/15 Net debt
Slide 20: Confirming 2016 Financial Guidance
Confirming 2016 Financial Guidance ($M) 2016 GAAP Guidance 2016 non-GAAP Guidance1 Makena sales $310 - $340 $310 - $340 Feraheme and MuGard sales $95 - $105 $95 - $105 Cord Blood Registry revenue $98 - $108 $115 - $1252 Total revenue $503 - $553 $520 - $570 Net income $0 - $30 $195 - $225 Operating
Slide 21: Portfolio Expansion: Acquire Products/Companies with Durable Growth
Portfolio Expansion: Leverage Expertise – Acquire Products/Companies with Durable Growth Opportunities Strong financial profile, management team & corporate infrastructure Commercial & Digital Expertise Maternal Health Hematology / Oncology, Nephrology & Hospital Future product CBR Makena® Velo opti
Slide 22: Executing on Key 2016 Milestones
Executing on Key 2016 Milestones 2016 Commercialize single-dose, preservative-free formulation Initiate definitive PK and comparative pain studies for subcutaneous auto-injector Initiate a head-to-head Phase 3 clinical trial in Q1-2016 evaluating the safety of Feraheme compared to Injectafer in adul
Slide 23: Q&A
AMAG Pharmaceuticals Q&A Q2-2016 Financial Results August 9, 2016 AMAG Pharmaceuticals
Slide 24: Appendix
AMAG Pharmaceuticals Appendix Q2-2016 Financial Results August 9, 2016 AMAG Pharmaceuticals
Slide 25: Reconciliation of Non-GAAP Adjustments to Net Income
Reconciliation of Non-GAAP Adjustments to Net Income for the 3- and 6- Months Ended June 30, 2016 and 2015 Three Months Ended Six Months Ended June 30, 2016 June 30, 2015 June 30, 2016 June 30, 2015 GAAP revenues $ 127,419 $ 123,884 $ 236,718 $ 213,389 Service revenues 5,053 4 — 13,614 4 — License f
Slide 26: Footnotes: Reconciliation of Non-GAAP Adjustments
Footnotes: Reconciliation of Non-GAAP Adjustments to Net Income for the 3- and 6- Months Ended June 30, 2016 and 2015 4 Represents purchase accounting adjustments related to deferred revenue in connection with the CBR acquisition. 5 Represents adjustments to exclude certain non-cash revenue associat
Slide 27: Reconciliation of GAAP to Non-GAAP Net Income and Adjusted Net Income Per Share
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and Adjusted Net Income Per Share for the 3- and 6-Months Ended June 30, 2016 and 2015 Three Months Ended Six Months Ended June 30, 2016 June 30,2015 June 30, 2016 June 30,2015 GAAP Net Income (Loss) $ (596) $ 33,258 $ (8,123) $ 46,162 Adjustments
Slide 28: Reconciliation of 2016 Financial Guidance of Non-GAAP Adjusted EBITDA and Net Income
Reconciliation of 2016 Financial Guidance of Non-GAAP Adjusted EBITDA and Non-GAAP Net Income ($M) 2016 Guidance GAAP net income $0 - $30 Adjustments: Interest expense, net $73 Provision for income tax $20 Operating income $93 - $123 Purchase accounting adjustments related to CBR deferred revenue $1
Slide 29: Share Count Reconciliation
Share Count Reconciliation 1 Employee equity incentive awards, Convertible notes and Warrants would be anti-dilutive in this period utilizing the “if-converted” method, which adjusts net income for the after-tax interest expense applicable to the convertible notes. 2 Reflects the Non-GAAP dilutive i
Slide 30: Capitalization as of June 30, 2016
Capitalization as of June 30, 2016 32 ($M) Cash, cash equivalents and investments $546 Convertible senior notes (2.5%) $200 Term loan facility (4.75%) 337 2023 senior notes (7.875%) 500 Total debt (principal amount outstanding) $1,037 ($M) Shares outstanding (M) 34.2 Net operating loss balance as of
Slide 31: CBR Non-GAAP Revenue Adjustment
CBR Non-GAAP Revenue Adjustment PURCHASE ACCOUNTING FUTURE IMPACT Deferred revenue balance on August 17, 2015 Addback to calculate non-GAAP revenue to be reported in future periods ($M) Purchase accounting rules require write-down of closing date deferred revenue on balance sheet at acquisition date
Slide 32: AMAG Pharmaceuticals Q2-2016 Financial Results
AMAG Pharmaceuticals Q2-2016 Financial Results August 9, 2016 AMAG Pharmaceuticals
Slide 33: amag
amag